INCY — INCYTE CORP catalysts

Name: Bio Catalyst Calendar — source-anchored biotech/pharma catalyst dates
Creator: Bio Catalyst Calendar
License: https://www.usa.gov/government-works

12 verified catalyst event(s) for INCYTE CORP (ticker INCY). Each is linked to its official source. Verified as of 2026-06-22.

Next verified catalyst

2026-06-22 — A Rollover Study to Provide Continued Treatment for Participants Previously Enrolled in St · official source ↗

Upcoming

Date	Event	Company	Drug	Official source & verification
2026-06-22 today ESTIMATED	READOUT A Rollover Study to Provide Continued Treatment for Participants Previously Enro Phase 2 · Myelofibrosis, Postlung Transplant (Bronchiolitis Obliterans)	INCY INCYTE CORP	itacitinib	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-07-03 in 11d ESTIMATED	READOUT A Ph1b/2 Study of Axatilimab Monotherapy in Chinese Participants With Recurrent Phase 1/2 · Chronic Graft-versus-host-disease	INCY INCYTE CORP	INCA034176	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-07-13 in 21d ESTIMATED	READOUT A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children and A Phase 3 · Atopic Dermatitis	INCY INCYTE CORP	Ruxolitinib, Vehicle Cream	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-07-22 in 30d ESTIMATED	READOUT A Study to Evaluate INCB099280 in Participants With Select Solid Tumors Who Are Phase 2 · Advanced Solid Tumor	INCY INCYTE CORP	INCB099280	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-07-30 in 1mo ESTIMATED	READOUT A Study to Evaluate INCB177054 in Participants With Select Advanced or Metastati Phase 1/2 · Solid Tumors, Advanced Solid Tumors	INCY INCYTE CORP	INCB177054, Retifanlimab	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-08-10 in 2mo ESTIMATED	READOUT A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Pa Phase 3 · NonSegmental Vitiligo	INCY INCYTE CORP	Ruxolitinib Cream, Vehicle Cream	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-09-01 in 2mo ESTIMATED	READOUT Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-interm Phase 3 · Diffuse Large B-cell Lymphoma	INCY INCYTE CORP	Tafasitamab, Lenalidomide, Rituximab, Cy	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-09-28 in 3mo ESTIMATED	READOUT A Study to Evaluate INCB099280 in Participants With Advanced Cutaneous Squamous Phase 2 · Cutaneous Squamous Cell Carcinoma	INCY INCYTE CORP	INCB099280	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-10-09 in 4mo ESTIMATED	READOUT Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants W Phase 3 · Hidradenitis Suppurativa	INCY INCYTE CORP	Ruxolitinib Cream, Vehicle Cream	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-10-09 in 4mo ESTIMATED	READOUT Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants W Phase 3 · Hidradenitis Suppurativa	INCY INCYTE CORP	Ruxolitinib Cream, Vehicle Cream	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-10-19 in 4mo ESTIMATED	READOUT A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participant Phase 3 · Prurigo Nodularis	INCY INCYTE CORP	Povorcitinib	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-10-19 in 4mo ESTIMATED	READOUT A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participant Phase 3 · Prurigo Nodularis	INCY INCYTE CORP	Povorcitinib	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change